Stoppen met roken is de grootste verandering die de meeste mensen voor hun eigen gezondheid kunnen maken, en het herstel begint dezelfde dag. Levenslange rokers verliezen ongeveer tien jaar levensverwachting, en stoppen geeft een groot deel daarvan terug, hoe eerder je stopt, hoe meer. Het is moeilijk, omdat nicotine verslavend is, en de methoden verschillen sterk in hoe goed ze werken. Gratis gedragsondersteuning en een telefonische stopplijn verbeteren je kansen.
Nicotinevervanging verhoogt die kansen verder, en varenicline is het krachtigste medicijn. E-sigaretten helpen sommige rokers om van tabak af te stappen, hoewel ze hun eigen risico's met zich meebrengen. Een lichte gewichtstoename in het eerste jaar komt vaak voor. De meeste rokers doen meerdere pogingen voordat ze definitief stoppen.
Findings & Outcomes
What It Is
Quitting smoking means stopping tobacco cigarettes for good. The difficulty is chemistry: nicotine reaches the brain within about 10 seconds of a puff and drives up dopamine. After months or years the brain adapts, so cutting nicotine off brings cravings, irritability, poor concentration, low mood, and broken sleep. The addictiveness is partly engineered: cigarette makers added ammonia to free-base the nicotine and speed its delivery, documented in the industry's own papers.
Because the dependence is physical, treating it as an addiction, with support and often medication, is what lifts the odds.
Separate the smoke from the nicotine. The smoke carries tar, carbon monoxide, and thousands of combustion chemicals, more than 70 of them carcinogens. That smoke causes most of the damage to the lungs, heart, and blood vessels. Nicotine is what makes smoking addictive. The tar and gases are what make it deadly. Each method here manages the nicotine so you can stop the smoke.
What It Does
The largest single gain from quitting is in how long and how well you live. In a US study of more than 200,000 adults, people who quit between 35 and 44 gained about nine years of life. Quitting before 40 avoided roughly 90% of the excess risk of dying early from continued smoking. The gains reach nearly every organ system (heart and arteries, lungs, gums, eyes, fertility, and asthma control) and they are larger the sooner you stop.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Longevity And Mortality
Quitting before 40 avoids about 90% of the excess risk of death; quitting at 35 to 44 gains about 9 years
In a study of more than 200,000 US adults, lifelong smokers died about a decade earlier than never-smokers, and quitting bought most of that back if you did it early: stopping in your late 30s gained about nine years, and quitting before 40 avoided roughly 90% of the extra risk of dying early from smoking.
Jha and colleagues linked smoking and cessation histories from the US National Health Interview Survey (participants interviewed 1997 to 2004) to deaths through 2006, with hazard ratios adjusted for age, education, adiposity, and alcohol. Current smokers aged 25 to 79 had roughly triple the all-cause mortality of never-smokers (HR for women 3.0, 99% CI 2.7 to 3.3; men 2.8, 99% CI 2.4 to 3.1). The probability of surviving from 25 to 79 was about twice as high in never-smokers (70% vs 38% in women, 61% vs 26% in men). Those who quit at 25 to 34, 35 to 44, and 45 to 54 gained about 10, 9, and 6 years of life; the authors concluded cessation before 40 reduces the excess mortality of continued smoking by about 90%.
Who this may not transfer to:Analyzed and reported separately for women and men, with closely similar mortality ratios and life-years gained in each.
The benefit is real at every age and larger the sooner you stop, so this is an argument to quit now, not a reason to think it is too late. Even quitting in the 50s or 60s adds years and lowers risk.
The study · 1
Jha et al., 21st-Century Hazards of Smoking and Benefits of Cessation in the United States · N Engl J Med 2013;368(4):341-350
Addiction
Varenicline more than doubled long-term quitting vs placebo (RR 2.24) and beat NRT and bupropion
Varenicline, a prescription pill, is the most effective single stop-smoking medication. In pooled trials it roughly doubled to tripled the chance of quitting for good compared with a dummy pill, and it outperformed both nicotine replacement and the other quit-smoking pill, bupropion.
Cahill and colleagues pooled 39 varenicline trials (27 in the primary placebo comparison, 12,625 participants). Standard-dose varenicline versus placebo gave a risk ratio for sustained abstinence at six months or longer of 2.24 (95% CI 2.06 to 2.43), graded high-certainty, NNT about 11. Varenicline beat bupropion (RR 1.39) and NRT (RR 1.25). Nausea was the most common adverse effect, usually mild to moderate and subsiding over time. A 2008 boxed warning raised concern about depressed mood and suicidal ideation, but the large EAGLES trial and subsequent analyses did not support a causal link with neuropsychiatric events, though evidence in people with current psychiatric illness is less conclusive.
Who this may not transfer to:Trials enrolled men and women; efficacy is well replicated across mixed populations.
Varenicline is a prescription and a decision to make with a clinician, and it can often be arranged through telehealth. It is the strongest single medication, works best alongside behavioral support, and the early neuropsychiatric concerns have not been borne out in the largest trial.
The study · 1
Cahill et al., Nicotine receptor partial agonists for smoking cessation (Cochrane review) · Cochrane Database Syst Rev 2016;5:CD006103
Across all licensed drugs, varenicline and combination NRT ranked the most effective quit aids
When every approved quit-smoking medication is compared in one analysis, two options come out on top and roughly tied: varenicline, and using two forms of nicotine replacement together. Both beat a single nicotine product or the pill bupropion, and all of them beat a dummy treatment.
Cahill and colleagues combined the direct and indirect evidence across the Cochrane reviews of nicotine replacement, bupropion, varenicline, and combinations, spanning 267 studies. Versus placebo, single-form NRT and bupropion each roughly increased quitting by about 80% (odds ratios near 1.8), while varenicline (OR about 2.9) and combination NRT (OR about 2.7) were highest. Varenicline was superior to single-form NRT and to bupropion; combination NRT and varenicline did not differ significantly from each other.
Who this may not transfer to:Network drew on trials enrolling men and women; rankings are consistent across the mixed evidence base.
The practical takeaway is that the two strongest options are varenicline and a patch-plus-fast-acting nicotine combination, so a person who cannot or would rather not take varenicline has a nearly equivalent over-the-counter route in combination NRT.
The study · 1
Cahill et al., Pharmacological interventions for smoking cessation: an overview and network meta-analysis · Cochrane Database Syst Rev 2013;5:CD009329
Nicotine replacement raised long-term quit rates by about 55% vs control (RR 1.55)
Nicotine replacement, such as patches, gum, lozenges, inhalers and sprays, raises the chance of quitting for good by roughly half again compared with going without. It works whether or not you also get counseling, and every licensed form helps.
Hartmann-Boyce and colleagues pooled 133 trials with 64,640 participants comparing NRT to placebo or no-NRT control. The overall risk ratio for abstinence at six months or more was 1.55 (95% CI 1.49 to 1.61), high-certainty. By form: gum 1.49, patch 1.64, oral tablets/lozenges 1.52, inhalator 1.90, nasal spray 2.02. Effects were largely independent of the definition of abstinence and the intensity of support. Adverse effects were product-specific and minor (skin irritation from patches, mouth irritation from gum), with serious events extremely rare.
Who this may not transfer to:Studies had similar numbers of men and women and the effect is well replicated in mixed populations.
NRT is available over the counter, works across all its forms, and does not require intensive counseling to help, which makes it the accessible first medication for most people. Using it correctly and at an adequate dose matters more than which single form you pick.
The study · 1
Hartmann-Boyce et al., Nicotine replacement therapy versus control for smoking cessation (Cochrane review) · Cochrane Database Syst Rev 2018;5:CD000146
Combination NRT (patch plus a fast-acting form) beat single-form NRT (RR 1.27)
Using two kinds of nicotine replacement at once, a steady patch plus a gum or lozenge for sudden cravings, works better than using just one. Higher-strength gum beats lower-strength, and starting the patch a week or two before your quit date may help as well.
Theodoulou and colleagues pooled 68 trials (43,327 participants) comparing types, doses, durations and timing of NRT. Combination NRT (fast-acting plus patch) versus single-form gave RR 1.27 (95% CI 1.17 to 1.37), high-certainty. A fast-acting form alone and a patch alone gave similar quit rates (RR 0.90, not significantly different). Preloading NRT before quit day helped (RR 1.25, 95% CI 1.08 to 1.44). Higher patch and gum doses tended to beat lower doses. Cardiac and serious adverse events were rare and measured inconsistently.
Who this may not transfer to:Trials enrolled men and women recruited from community and clinic settings; the combination benefit is consistent across them.
The practical move is a patch for a steady background level plus gum or lozenge for breakthrough cravings, at an adequate strength, both available over the counter. This combination sits alongside varenicline as one of the two most effective drug options.
The study · 1
Theodoulou et al., Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation (Cochrane review) · Cochrane Database Syst Rev 2023;6:CD013308
Nicotine e-cigarettes beat nicotine replacement for quitting (RR 1.55), at high certainty
Vaping nicotine helps people quit smoking better than nicotine patches or gum do, and the evidence for that is now graded high-certainty. It works for some people who could not quit other ways, and short-term side effects are similar to nicotine replacement.
Lindson and colleagues maintain this as a living systematic review, most recently updated to March 2025. Nicotine EC versus NRT gave RR 1.55 (95% CI 1.28 to 1.88; I2 = 0%; 9 studies, 2,703 participants), high-certainty, translating to about 3 additional quitters per 100. Nicotine EC also beat behavioral or no support. Adverse-event rates were similar between EC and NRT (RR about 1.01), and serious adverse events were rare with wide confidence intervals. The most consistent short-term complaint with e-cigarettes was throat and mouth irritation.
Who this may not transfer to:Trials enrolled men and women who smoked; the cessation benefit is consistent across the mixed evidence base.
For a smoker who has tried and failed with other methods, switching to a nicotine e-cigarette is an evidence-based route off tobacco. The caveats are that it is not risk-free, its long-term effects are unknown, and it is not for people who never smoked, all covered in the cautions.
The study · 1
Lindson et al., Electronic cigarettes for smoking cessation (Cochrane living review) · Cochrane Database Syst Rev 2025;11:CD010216
In a UK trial, e-cigarettes nearly doubled 1-year quitting vs nicotine replacement (18.0% vs 9.9%)
In a large UK trial, twice as many people quit smoking for a year with an e-cigarette as with nicotine patches or gum (18% versus 10%). The catch was that most of those who quit with the e-cigarette were still vaping a year later, while most who quit with nicotine replacement had stopped that too.
Hajek and colleagues randomized 886 adults in UK National Health Service stop-smoking services to an e-cigarette starter kit (18 mg/mL nicotine, second-generation refillable) or NRT of their choice including combinations, both for up to 3 months, plus at least 4 weeks of behavioral support. Biochemically validated sustained one-year abstinence was 18.0% with e-cigarettes versus 9.9% with NRT (RR 1.83, 95% CI 1.30 to 2.58, P<0.001). Throat and mouth irritation was more common with e-cigarettes (65.3% vs 51.2%). Among one-year abstainers, continued use of the assigned product was 80% for e-cigarettes versus 9% for NRT.
Who this may not transfer to:Both sexes enrolled; the participants were motivated smokers already seeking help, so the absolute quit rates may be higher than in the general smoking population.
This is the landmark head-to-head trial behind current e-cigarette guidance. It shows e-cigarettes can outperform standard nicotine replacement for quitting, while flagging the trade-off that ongoing use is common, so the aim is to taper off the device eventually.
The study · 1
Hajek et al., A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy · N Engl J Med 2019;380(7):629-637
Behavior Change
Behavioral support raised quitting, and works best combined with medication
Counseling and structured behavioral support, in person, by phone, or by text, raise the chance of quitting. They help most when paired with a medication, so support plus a drug beats either on its own.
Hartmann-Boyce and colleagues synthesized 312 behavioral-intervention studies. Behavioral support of increasing intensity improved abstinence, and the combination of behavioral support with pharmacotherapy outperformed either component alone. The overview drew together telephone counseling, in-person counseling, print and digital support, and financial-incentive approaches, with incentives and combined pharmacotherapy-plus-support among the more effective strategies.
Who this may not transfer to:Behavioral trials enrolled men and women broadly; the benefit of support and of combining it with medication is consistent across mixed populations.
Because support and medication stack, the strongest practical plan is a medication plus some structured support, and the support can be free (a quitline, a text program, an app), which makes stacking accessible to anyone.
The study · 1
Hartmann-Boyce et al., Behavioural interventions for smoking cessation: an overview and network meta-analysis · Cochrane Database Syst Rev 2021;1:CD013229
Telephone quitline counseling increased quitting, more with repeated calls
Calling a stop-smoking helpline and getting counseling raises the chance of quitting, and getting several call-back sessions works better than a one-off call. In the US the free national quitline is 1-800-QUIT-NOW.
Matkin and colleagues reviewed 104 trials of proactive telephone counseling. Multi-session call-back counseling increased quitting relative to a single call or self-help (pooled relative risk in the range 1.38 to 1.42 across the main analyses), and there was a dose-response by number of calls. Telephone counseling also added benefit when combined with pharmacotherapy or with in-person contact. Quitlines are free to the caller in many countries, which makes them a widely accessible support option.
Who this may not transfer to:Quitline trials enrolled men and women across many countries; the benefit of proactive multi-session counseling is consistent.
A quitline is free, evidence-based, and available to anyone with a phone, so it is one of the most accessible ways to add behavioral support to a quit attempt; asking for several call-back sessions, not a single call gets more out of it.
The study · 1
Matkin et al., Telephone counselling for smoking cessation (Cochrane review) · Cochrane Database Syst Rev 2019;5:CD002850
Heart And Vascular
Quitting cut cardiovascular events sharply within 5 years (HR 0.61 vs current smokers)
In heavy smokers, quitting cut the rate of heart attacks, strokes and heart failure by about 39% within five years compared with people who kept smoking. Risk kept dropping after that, though it took roughly 10 to 15 years to come down close to a never-smoker's.
Duncan and colleagues analyzed 8,770 Framingham participants (5,308 ever-smokers, median 17.2 baseline pack-years) over a median 26.4 years, with 2,435 first cardiovascular events. Compared with current smoking, quitting within 5 years was associated with lower incident CVD (HR 0.61, 95% CI 0.49 to 0.76). Compared with never smoking, former smokers' risk stopped being significantly elevated only between 10 and 15 years after cessation (HR at 10 to under 15 years 1.25, 95% CI 0.98 to 1.60). CVD here meant myocardial infarction, stroke, heart failure, or cardiovascular death.
Who this may not transfer to:Cohort was about 45% male; associations were reported for the pooled population and are consistent with the wider cessation literature in both sexes.
The fast early drop is the encouraging part: much of the cardiovascular benefit of quitting arrives in the first five years. That former-smoker risk stays a little above never-smoker for a decade or more is a reason to quit sooner, not a reason to doubt the gain.
The study · 1
Duncan et al., Association of Smoking Cessation With Subsequent Risk of Cardiovascular Disease · JAMA 2019;322(7):642-650
Cancer Risk And Outcome
Lung cancer risk falls after quitting but stays elevated for years in heavy former smokers
Quitting steadily lowers the risk of lung cancer, with a meaningful drop within the first five years, but for someone who smoked heavily for a long time some extra risk lingers for decades. Stopping is worth it at any point, and the earlier the better.
Tindle and colleagues followed 8,907 Framingham participants over about 28.7 years, recording 284 incident lung cancers, 93% of them in people with more than 21 pack-years. Compared with current heavy smokers, former heavy smokers had lower lung cancer risk that fell with time since quitting (HR 0.61 within 5 years of cessation), but relative to never-smokers, risk in the heaviest smokers remained elevated more than 25 years after quitting. The study underscored both the benefit of quitting and the lasting risk that justifies lung cancer screening in long-term former smokers.
Who this may not transfer to:Pooled mixed-sex cohort; the dose-response and decline after cessation are consistent with the wider epidemiology in both sexes.
The lasting risk in long-term smokers is the reason lung cancer screening (low-dose CT) is offered to older people with a heavy smoking history even years after they quit; a person can ask about eligibility themselves. It is an argument for quitting early, and for screening if you smoked heavily, not against quitting.
The study · 1
Tindle et al., Lifetime Smoking History and Risk of Lung Cancer: Results From the Framingham Heart Study · J Natl Cancer Inst 2018;110(11):1201-1207
Fertility
Smoking lowers sperm count, motility and normal shape (meta-analysis of 5,865 men)
Men who smoke tend to have lower sperm count, poorer sperm movement, and fewer normally shaped sperm than men who do not, and the effect is bigger the more they smoke. For a man trying to conceive, not smoking is one of the changeable factors that matters.
Sharma and colleagues pooled studies of 5,865 men, accounting for the 2010 WHO change in semen analysis methods. Smoking was associated with lower sperm concentration (mean difference -9.72 x10^6/mL, 95% CI -13.32 to -6.12), lower motility (MD -3.48%, 95% CI -5.53 to -1.44), and lower normal morphology (MD -1.37%, 95% CI -2.63 to -0.11). Subgroup analysis showed a larger effect in moderate-to-heavy smokers and in men from infertility clinics.
Who this may not transfer to:Semen quality is a male measure, so this claim applies to men only.
Because these semen parameters can recover after quitting as new sperm are produced over roughly a three-month cycle, stopping smoking is a practical step for a man trying to conceive, alongside the general fertility basics.
The study · 1
Sharma et al., Cigarette Smoking and Semen Quality: A New Meta-analysis · Eur Urol 2016;70(4):635-645
Oral Health
A quitter's gum-disease risk returns close to a never-smoker's; smokers carry about 80% higher risk
Smoking is a major cause of gum disease, and quitting reverses much of that risk: a former smoker's chance of developing or worsening periodontitis comes back close to that of someone who never smoked, while current smokers carry about 80% more risk. Quitters also heal better after gum treatment.
Leite and colleagues pooled prospective longitudinal and interventional studies. Quitters versus never-smokers: RR 0.97 (95% CI 0.87 to 1.08), essentially no excess risk. Smokers versus quitters: RR 1.79 (95% CI 1.36 to 2.35); smokers versus never-smokers: RR 1.82 (95% CI 1.43 to 2.31). After non-surgical periodontal therapy at 12 to 24 months, quitters gained up to 0.2 mm more clinical attachment (95% CI -0.32 to -0.08) and 0.32 mm more pocket-depth reduction (95% CI 0.07 to 0.52) than non-quitters.
Who this may not transfer to:Periodontal studies enrolled men and women; the reversal of risk after quitting applies to both.
For gum health the message is encouraging: much of smoking's damage to periodontal risk reverses after quitting, and stopping improves how well gum treatment works, so do it before or alongside periodontal care.
The study · 1
Leite et al., Impact of Smoking Cessation on Periodontitis: A Systematic Review and Meta-analysis · Nicotine Tob Res 2019;21(12):1600-1608
Vision
Current smoking is one of the few strong, consistent risk factors for late macular degeneration
Smoking is one of the few strong, changeable risk factors for age-related macular degeneration, a leading cause of losing central vision as people age. Among the many things studied, current smoking stood out as consistently linked to the worst form of the disease.
Chakravarthy and colleagues screened studies of late AMD with estimates for 16 pre-selected risk factors and ran fixed-effects meta-analyses. Increasing age, current cigarette smoking, previous cataract surgery, and family history of AMD showed strong and consistent associations with late AMD, while factors such as body mass index, cardiovascular history, and higher plasma fibrinogen were moderate, and gender, ethnicity, diabetes, and iris color were weaker or inconsistent. Smoking is the principal modifiable factor among the strong associations.
Who this may not transfer to:Risk-factor studies enrolled men and women; smoking is a consistent AMD risk factor in both.
Because smoking is the main changeable risk factor here, quitting is the clearest way to lower a person's added risk of this form of vision loss, and the risk in former smokers declines over years toward that of never-smokers.
The study · 1
Chakravarthy et al., Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis · BMC Ophthalmol 2010;10:31
Sexual Function
Quitting smoking was associated with improved erectile function over 6 months
In a study of men who smoked and had erectile problems, those who managed to quit tended to see their erectile function improve over six months. Smoking narrows the small arteries an erection depends on, and stopping helps them recover.
Chan and colleagues randomized 719 Chinese men with erectile dysfunction who smoked to smoking-cessation counseling with brief NRT versus brief quitting advice. The intervention increased abstinence (self-reported 23% vs 12.8%, RR 1.79, 95% CI 1.22 to 2.62; validated 11.4% vs 5.5%, RR 2.07, 95% CI 1.13 to 3.77). Improvement in erectile dysfunction from baseline to 6 months was associated with self-reported quitting at 6 months, not with intervention assignment, meaning it tracked with actually stopping, not with being offered help.
Who this may not transfer to:Erectile function is a male outcome, so this claim applies to men only.
The mechanism is vascular: erections depend on healthy small-artery blood flow, which smoking impairs, so quitting is one of the modifiable steps that can improve erectile function alongside exercise and cardiovascular health.
The study · 1
Chan et al., Smoking-cessation and adherence intervention among Chinese patients with erectile dysfunction · Am J Prev Med 2010;39(3):251-258
Respiratory
Smokers with asthma who quit gained about 400 mL of lung function within 6 weeks
Smokers with asthma who managed to quit had noticeably better lung function within six weeks, gaining roughly 400 mL on a breathing test compared with those who kept smoking. Smoking also makes asthma inhalers work less well, so quitting helps the treatment work too.
Chaudhuri and colleagues offered smokers with asthma the option to quit or continue. Of 32 recruited, 10 quit for 6 weeks and 11 continued. Compared with continuing smokers at 6 weeks, quitters had a mean FEV1 difference of 407 mL (95% CI 21 to 793, p=0.039) and a fall in sputum neutrophil count, indicating less airway inflammation. Corticosteroid responsiveness measures did not change over the short 6-week window. The background is that active smoking worsens asthma symptoms, accelerates lung-function decline, and impairs the response to inhaled corticosteroids.
Who this may not transfer to:Small mixed-sex study; the lung-function gain is consistent with the wider evidence that active smoking harms asthma control, though the sample is small.
For a smoker with asthma, quitting both improves lung function directly and restores some of the effect of inhaled steroid treatment, making it one of the highest-value changes for asthma control.
The study · 1
Chaudhuri et al., Effects of smoking cessation on lung function and airway inflammation in smokers with asthma · Am J Respir Crit Care Med 2006;174(2):127-133
How It Works
Quitting reverses different harms at different speeds. The quickest change is in blood gases and vessel tone. Carbon monoxide from smoke binds hemoglobin and crowds out oxygen, and nicotine narrows blood vessels and speeds the heart. Within hours of the last cigarette, nicotine's half-life is about two hours, the blood carries more oxygen, and heart rate and blood pressure settle. The slower changes take months to years. One is the airway lining, chronically inflamed, its clearing hairs (cilia) paralyzed by smoke. The other is the artery walls and DNA, where years of exposure raise the long-run risk of heart disease and cancer.
Anatomy of the Practice
1The first day
Nicotine and carbon monoxide clear quickly. Heart rate and blood pressure, pushed up by nicotine, begin to fall within about 20 minutes. The carbon monoxide in the blood drops to a non-smoker's level within roughly a day. Oxygen delivery then returns to normal. Withdrawal also begins now: the cravings and irritability are the brain adjusting to the missing nicotine.
2The first weeks to months
Withdrawal symptoms peak in the first week and ease over two to four weeks. Over one to three months, inflammation in the airway lining settles and the cilia start clearing mucus again. The smoker's cough and breathlessness lessen, and lung function on spirometry improves. Appetite returns, and taste and smell sharpen. That is part of why weight tends to rise in this window.
3The first years
As the arteries and airways recover, the risk of a heart attack or stroke falls substantially within about five years. It keeps falling toward a never-smoker's level over the next decade. The risk of lung, mouth, throat, and other smoking-related cancers declines over years, the longer you stay stopped, the more. For a long-term heavy smoker, some raised lung-cancer risk persists for many years.
The Methods That Work
Most people try on willpower alone, and most of those attempts fail: only about 3 to 5% are still smoke-free a year later. A proven method raises the odds. Behavioral support and a phone quitline lift anyone's chances and are the place to start. Nicotine replacement, a prescription pill, and e-cigarettes add more on top. Each layer you add stacks on the last.
Ways to Do It
Pick a quit date, line up support before it, and give yourself proper tools. Most people do best combining behavioral support with one of the medications.
Choose a date within the next two weeks, tell the people around you, and clear cigarettes, lighters and ashtrays out. Then line up free behavioral support: in the US the national quitline is 1-800-QUIT-NOW, and there are free text-message programs and apps. Telephone counseling and structured behavioral support measurably raise quit rates on their own, and cost nothing.
Cravings are short, usually three to five minutes, and they pass whether or not you smoke. Have a plan for the situations that trigger you: coffee, alcohol, stress, the drive to work: delay, breathe slowly, drink water, walk, keep your hands and mouth busy. Withdrawal is worst in the first days, so front-load your support there.
Nicotine replacement therapy (NRT) supplies nicotine without the smoke, taking the edge off cravings so you can break the habit. It raises quit rates by about half again over willpower alone. A nicotine patch gives a steady background, and a fast-acting form, gum or lozenge, handles breakthrough cravings. Using both together works better than either alone, and both are sold over the counter. Starting the patch a week or two before your quit date may help further.
Varenicline (Champix or Chantix) is a prescription pill that blunts both withdrawal and the reward from smoking. It roughly doubles to triples the chance of quitting for good, the strongest single medication. It outperforms both nicotine replacement and the other quit-smoking pill, bupropion. It needs a prescription, which a doctor or telehealth service can provide. Nausea is the most common side effect and usually fades.
For a smoker who has struggled to quit with support and medication, switching fully to an e-cigarette (vaping) helps some people get off tobacco. It is a large step down in harm from cigarettes. The cessation trials enrolled established smokers; the effect in people who never smoked has not been studied.
Bupropion (Zyban) is a non-nicotine prescription pill that reduces cravings. It is a reasonable choice for someone who does not want varenicline or has a reason to avoid it. It is less effective than varenicline in head-to-head trials but clearly better than an unaided attempt, and it can be combined with nicotine replacement.
Go Deeper
- Erectile dysfunction: the blood-flow reasons smoking causes it, and what recovers once you stop.
- Male fertility: where smoking sits among the reversible causes of poor sperm quality.
- Macular degeneration: the eye disease smoking makes more likely, and why stopping matters.
- Periodontitis: smoking, gum disease, and what changes for a former smoker.
- Asthma: how smoking worsens control, and what shifts after a smoker with asthma quits.
The Chinese Medicine View
Chinese medicine has no category for cigarettes, and it would be an invention to claim the tradition anticipated them. What it offers is a way of reading smoke, heat, and dryness in the body.
The tradition reads tobacco smoke as a hot, drying, acrid influence that enters through the Lung. The Lung governs the breath and the body's surface defenses. Long exposure is understood to consume the Lung's Yin (its cooling, moistening aspect) and to generate heat and phlegm. That picture fits the dry cough, the thick mucus, and the heat signs a long-term smoker often shows. The craving and agitation of withdrawal might be read through Liver patterns, where stagnation and rising Yang produce irritability and restlessness.
The tradition would not treat every quitter alike. Someone dry and depleted, with a red tongue and a hacking dry cough, is read very differently from someone damp and phlegm-laden. Acupuncture and herbs are matched to that individual pattern, and smoking itself is never handled as one fixed diagnosis. Acupuncture is sometimes offered as an aid to stopping, and it is popular, though controlled trials have not shown it to reliably outperform sham needling for quit rates. Offered as supportive care, it may steady someone through a rough few weeks.
Cautions For This Practice
Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
Quitting is followed by about 9 to 11 pounds of weight gain over a year, mostly in the first 3 months
Aubin and colleagues pooled 62 studies of quitters with prolonged abstinence up to 12 months. Mean weight gain in untreated quitters was 1.12 kg at 1 month, 2.26 kg at 2 months, 2.85 kg at 3 months, 4.23 kg at 6 months, and 4.67 kg at 12 months. Using the weighted standard deviations, at 12 months about 16% lost weight, 37% gained under 5 kg, 34% gained 5 to 10 kg, and 13% gained more than 10 kg. Weight gain was similar whether or not people used cessation medication and whether or not they were especially concerned about weight.Aubin et al., Weight gain in smokers after quitting cigarettes: meta-analysis
Varenicline's main side effect is nausea; the early mood and suicidality warning was not confirmed as causal
In Cahill and colleagues' Cochrane review, nausea was the most frequently reported varenicline adverse effect, mostly mild to moderate and tending to subside. A pooled analysis suggested a possible 25% relative increase in serious adverse events (RR 1.25, 95% CI 1.04 to 1.49), but most were comorbid events (infections, cancers, injuries) judged unrelated to treatment, and higher losses to follow-up in control groups likely understated control-arm rates. The EAGLES trial, designed to test the neuropsychiatric signal, did not support a causal link with mood or suicidal behavior in people without and with stable psychiatric conditions.Cahill et al., Nicotine receptor partial agonists for smoking cessation (Cochrane review)
Withdrawal is uncomfortable and temporary
Cravings, irritability, low mood, poor concentration, restlessness and disturbed sleep are all withdrawal. They peak early and mostly settle within a few weeks. If low mood is severe or persistent, or you have a history of depression, arrange support in advance. Quitting can unmask or worsen low mood in some people.
Some medications need a dose review when you stop
Chemicals in tobacco smoke speed the liver's clearance of several drugs, so quitting can raise the blood levels of some of them. This matters for a few specific medicines, including certain psychiatric drugs (such as clozapine and olanzapine), theophylline, and insulin, where the dose may need adjusting after you stop. If you take a regular prescription medication, mention that you are quitting to whoever prescribes it.
E-cigarettes: lower harm, not zero harm
Vaping exposes you to far fewer toxicants than cigarettes. It still is not harmless. Throat and mouth irritation are common, and its long-term effects are not yet known. The nicotine addiction continues, so many people who switch keep using the device long term.
Expect some weight gain, and keep it in proportion
Most people gain about 9 to 11 pounds over the first year, most of it in the first three months. Appetite returns and metabolism resettles. The range is wide: some lose weight, and some gain much more. The health gain from stopping smoking far outweighs this. Staying active and eating well through the first months keeps it down.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
Common Questions
Are e-cigarettes a safe way to quit?
They help some people quit, but "safe" overstates it. In a UK trial they roughly doubled the one-year quit rate against nicotine patches, and Cochrane's living review now rates them more effective than nicotine replacement at high certainty. Against that, the nicotine dependence remains and the long-term effects are still unknown.
Does quitting help with things like erections, fertility, and gum disease?
Yes, in ways that show up on measurements. Smoking narrows the small arteries that erections depend on, and stopping is linked to better erectile function. It also lowers sperm count, movement, and normal shape, so quitting matters for a man trying to conceive. A former smoker's risk of gum disease (periodontitis) falls close to a never-smoker's, and quitting improves how gum treatment works. Smoking is one of the few strong, changeable risk factors for age-related macular degeneration, a leading cause of vision loss. For a smoker with asthma, lung function improves within weeks of stopping.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 18 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 11, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.